Navigation Links
Accera, Inc. Announces Open-Label Data from Phase II Study in,Alzheimer's Disease at International Conference on Prevention of,Dementia

xtension rapidly showed significant improvement in memory and cognition, while AC-1202 appeared to have a disease stabilizing effect on subjects expressing the ApoE4 genotype (ApoE4(-)). Regardless of genotype, all subjects who remained on AC- 1202 for all nine months of the study showed very little disease progression, declining only 0.8 points below baseline in ADAS-Cog scores in contrast to the 5.4-point decline observed in placebo subjects extrapolated to nine months.

"The significant and rapid cognitive improvements observed in ApoE4(-) patients support the efficacy observed in our Phase IIa study," said Dr. Lauren Costantini, Accera's vice president of clinical development. "It also provides further evidence of the link between Alzheimer's disease and neuronal hypometabolism," she added, referring to AC-1202's novel mechanism of action.

AC-1202 continued to be well tolerated by subjects in the open-label extension study, providing an additional six months of safety data. The incidence of treatment-related gastrointestinal side effects was similar to that of other AD drugs in the double-blind phase of the study, but a reformulated version of AC-1202 used in the open-label extension study greatly reduced these side effects.

"The excellent safety profile of AC-1202 in addition to its efficacy on top of existing AD drugs makes it a strong candidate for a co-therapeutic approach to the treatment of Alzheimer's disease," said Dr. Steve Orndorff.

Open-label results were highlighted in a "Late Breaking News" press conference today at 1:30 p.m. (EDT) by the Alzheimer's Association. The 2nd Annual International Conference on Prevention of Dementia, a multidisciplinary forum for professionals from the fields of bench research, drug discovery, medicine, care and public policy, is hosted by the Alzheimer's Association, the leading voluntary health organization in Alzheimer care, support and research.

About AC-1202

Brain imaging tec
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Accera, Inc. Announces Results of Phase II Study in Alzheimers Disease at American Academy of Neurology Meeting
2. Accera, Inc. to Present Results of Phase II Study in Alzheimers Disease at American Academy of Neurology Meeting
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:6/18/2013)... N.J. , June 18, 2013  Actavis, Inc. (NYSE: ... Actavis") has filed with the U.S. Securities and Exchange Commission ... Actavis, proposed acquisition of Warner Chilcott plc (NASDAQ: ... of Actavis and Warner Chilcott (the "Form S-4"). ... and Warner Chilcott have entered into a definitive ...
(Date:6/18/2013)... June 18, 2013  Recent regulatory and budget challenges ... Education groups at large pharmaceutical companies to effectively educate ... effective use of their new products. With the pressure ... is crucial that these "Med Ed" groups ... To address the changes that are transforming the ...
(Date:6/18/2013)... LEANDRO, Calif. , June 18, 2013  Cataracts ...  According to the American Association of Ophthalmology, aging is ... a clouding of the eye,s natural lens. 22 million ... 2020, as Baby Boomers continue to age, that number ... high tech world of iPhones, iPads, smart-phones and computers, ...
Breaking Medicine Technology:Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 2Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 3Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 4Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 5Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 6Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 7Though Vital to Educating Doctors on New Products, Pharma "Med Ed" Groups Working Under Huge Internal & External Constraints 2New Vision Hope For Millions Undergoing Cataract Surgery 2New Vision Hope For Millions Undergoing Cataract Surgery 3
... LLC ("Deston") announced today that it is currently exploring its ... Otic Solution ("Auralgan") by the Federal Government and that it ... product. "Despite the recent actions by the ... effective treatment for ear pain and inflammation," said David Preston ...
... N.J., Feb. 25, 2011 ConvaTec, a world-leading developer ... hospital care, today announced a new appointment to its ... Senior Vice President and Chief Quality Officer for ConvaTec ... member of the ConvaTec Executive Committee. McNally will be ...
Cached Medicine Technology:Deston Therapeutics Stands By Safety and Efficacy of Auralgan After FDA Action 2Deston Therapeutics Stands By Safety and Efficacy of Auralgan After FDA Action 3Deston Therapeutics Stands By Safety and Efficacy of Auralgan After FDA Action 4
(Date:6/18/2013)... Palo Alto has taken yet another step ... with its recent major long-term solar power commitment. , ... electric power purchase agreements , which together will result in ... photovoltaic electric power per year, which is the equivalent of ... enough power to supply all 65,000+ Palo Alto residents---and then ...
(Date:6/18/2013)... Sun Buick GMC, Moosic, is sponsoring the hole-in-one contest at ... on Thursday, June 20, at Irem Country Club, Dallas, Pennsylvania. ... Verano and will go to the lucky golfer at the ... , The MFHS golf tournament is open to all interested ... crew team for 18 holes. The fee is $125 per ...
(Date:6/18/2013)... 2013 Internationally acclaimed plastic surgeon, ... thebestbreast.com, showcasing his unique approach to breast augmentation. ... his surgical method and highlights the results of ... website, Dr. Tebbetts compares his breast augmentation method ... Tebbetts’ method does not necessitate the use drains, ...
(Date:6/18/2013)... Hospitals Case Medical Center clinical researchers have launched ... which will evaluate the ability of a patient,s ... end stage peripheral arterial disease (PAD). , ... Surgery at University Hospitals Case Medical Center,s Harrington ... at Case Western Reserve University School of Medicine, ...
(Date:6/18/2013)... signaling network between two previously unconnected proteins, exposing a ... growth at its starting point. , A team led ... Cancer Center reported the tie between epidermal growth factor ... a protein vital to the first step in DNA ... . , "MCM7 overexpression marks cell proliferation and is ...
Breaking Medicine News(10 mins):Health News:Palo Alto Seals the Deal on Major Solar Electric Investments 2Health News:Palo Alto Seals the Deal on Major Solar Electric Investments 3Health News:Internationally Acclaimed Breast Augmentation Expert Announces the Launch of His New Website 2Health News:UH Case Medical Center launches novel clinical trial using stem cells to prevent amputation 2Health News:Scientists catch EGFR passing a crucial message to cancer-promoting protein 2
... images offers the possibility of using magnetic resonance imaging ... path of many degenerative brain diseases, report scientists at ... of California, San Francisco. The technique, developed by ... Bruce Miller, MD, clinical director of the UCSF Memory ...
... , TUESDAY, April 10 (HealthDay News) -- Black people with ... cardiac death than whites or other racial groups who suffer ... was true regardless of blacks, other risk factors, such as ... Researchers examined 533 black and 8,660 non-black patients ...
... passed the motor vehicle administration,s vision test may not mean ... found that the frequency and distance at which drivers with ... night was severely reduced, even when the drivers have passed ... are very common and lots of people with these conditions ...
... in low- and middle-income countries, and there is an ... help tackle the disease, states an analysis in CMAJ ... more people than HIV/AIDS, tuberculosis and malaria combined. The ... rise through 2030 of 82% in low- and lower-income ...
... San Diego, CA - The American Society of Pediatric ... April 22, during the 2012 Combined Otolaryngology Spring Meetings ... in San Diego, CA. During the ASPO meeting, ... scientific sessions featuring expert panelists will be presented focusing ...
... Doheny HealthDay Reporter , MONDAY, April 9 ... protect against repeat heart attacks, strokes or other cardiovascular ... surprised at these findings because I assumed that there ... Dr. Seung-Kwon Myung, chief of the carcinogenesis branch of ...
Cached Medicine News:Health News:New MRI technique may predict progress of dementias 2Health News:High Blood Pressure May Be Especially Lethal for Blacks 2Health News:Can a standard vision test predict nighttime driving performance? 2Health News:Scientific session and new research highlights 2Health News:Omega-3 Supplements No Help Against Repeat Heart Trouble: Review 2Health News:Omega-3 Supplements No Help Against Repeat Heart Trouble: Review 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: